PepGen Inc.

NASDAQ:PEPG

Biotechnology

Healthcare
$3.88 +5.29%

+$0.09 today

Market cap
$268.73M
Beta
1.93
P/E (TTM)
-1.6
EPS (TTM)
-$1.12
52W Low $1.01High $7.80

Volume 5.61M

Average 1.37M

PEPG Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

PepGen Inc.NASDAQ: PEPG

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development declines year over year

Q1 FY2026 research & development of $12.69M fell 50.0% year over year, behind the -32.7% change in trailing-twelve-month research & development. Sequentially, it fell 10.6% from the prior quarter. Over 3 fiscal years it compounded at +9.5% a year.

Context

  • Research & development increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -50.0% toward the trailing-twelve-month pace of -32.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$12.69M-10.6% QoQ
Last fiscal yearDec 2025
$71.04M-7.1% YoY
LTMMar 2026
$58.35M-32.7% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-50.0%——
1 year-7.1%——
3-year CAGR+9.5%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
71.04M USD
Year-over-year change
-7.1%
4-year CAGR
+31.4%

Research & Development vs competitors

How PEPG compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -32.7% is the 7th highest of 8, against a peer median of -19.6%.
  • Over three fiscal years its annual growth of +9.5% compares with a peer median of -0.2%.
PEPG Competitors
Research & Development for PEPG and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ALECAlector, Inc.LTM Mar 2026$114.68M USD-37.7%-16.4%622.7%
FATEFate Therapeutics, Inc.LTM Mar 2026$100.48M USD-23.9%-30.4%1590.8%
NKTXNkarta, Inc.LTM Mar 2026$88.91M USD-7.1%-0.2%—
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 2026$74.27M USD+76.4%+63.2%—
PEPGPepGen Inc.LTM Mar 2026$58.35M USD-32.7%+9.5%—
MOLNMolecular Partners AGLTM Mar 2026CHF 46.97M CHF-1.7%-7.5%—
CRDFCardiff Oncology, Inc.LTM Mar 2026$31.62M USD-19.6%+9.2%6022.3%
ELTXElicio Therapeutics, Inc.LTM Mar 2026$23.84M USD-29.5%+13.5%—
Peer median (excluding PEPG) —-19.6%-0.2%1590.8%

Competitors are the stored peer set for PEPG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue001.18M1.51M1.4M
Gross Profit00(1.18M)(1.51M)(1.4M)
Gross Margin—————
Research & Development23.8M54.08M68.13M76.48M71.04M
Selling, General & Admin8.11M14.22M16.64M21.26M22.57M
Operating Expenses27.11M68.3M83.58M96.23M92.22M
Depreciation & Amortization178K493K1.18M1.51M1.4M
EBITDA(27.1M)(64.91M)(77.37M)(89.09M)(88.21M)
EBITDA Margin—————
Operating Income(27.11M)(68.3M)(84.77M)(97.74M)(93.61M)
Operating Margin—————
Interest Income02.79M6.4M7.14M4.02M
Interest Expense00000
Other Income / Expenses(172K)2.9M6.21M7.14M4.01M
Income Before Tax(27.28M)(65.4M)(78.55M)(90.6M)(89.61M)
Pre-Tax Margin—————
Income Tax Expense03.71M73K(617K)49K
Net Income(27.28M)(69.1M)(78.63M)(89.98M)(89.66M)
Net Margin—————
EPS (Basic)(1.22)(4.42)(3.30)(2.85)(2.12)
EPS (Diluted)(1.22)(4.42)(3.30)(2.85)(2.12)
Weighted Avg Shares22.39M15.64M23.8M31.58M42.22M
Weighted Avg Shares (Diluted)22.39M15.64M23.8M31.58M42.22M

PepGen Inc.

NASDAQ:PEPG

Intrinsic Alpha fair value

Locked

Current Price

$3.88

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.